Age (years) Median (range) |
67 (43−85) |
67 (48−80) |
67 (43−85) |
p = 0.51 |
Clinical stage |
|
|
|
|
cT1a N0 |
2 (1.8%) |
1 (2.6%) |
1 (1.4%) |
|
cT1b N0 |
47 (42.8%) |
20 (52.6%) |
27 (37.5%) |
|
cT1c N0 |
59 (53.6%) |
17 (44.8%) |
42 (58.3%) |
p = 0.42 |
cT1b N1 |
1 (0.9%) |
0 (0.0%) |
1 (1.4%) |
|
cT2 N0 |
1 (0.9%) |
0 (0.0%) |
1 (1.4%) |
|
Histological type |
|
|
|
|
Ductal carcinoma in situ (DCIS) |
1 (0.9%) |
1 (2.6%) |
0 (0.0%) |
|
Invasive ductal carcinoma |
70 (63.6%) |
26 (68.4%) |
44 (61.1%) |
p = 0.46 |
Invasive lobular carcinoma |
19 (17.3%) |
5 (13.2%) |
14 (19.45%) |
|
Others |
20 (18.2%) |
6 (15.8%) |
14 (19.45%) |
|
Multifocal disease |
6 (5.4%) |
4 (10.5%) |
2 (2.8%) |
p = 0.21 |
Pathological Stage pT |
|
|
|
|
pTis |
1 (0.9%) |
1 (2.6%) |
0 (0.0%) |
|
pT1a |
3 (2.7%) |
0 (0.0%) |
3 (4.2%) |
|
pT1b |
41 (37.3%) |
16 (42.1%) |
25 (34.7%) |
p=0.40 |
pT1c |
59 (53.6%) |
20 (52.6%) |
39 (54.2%) |
|
pT2 |
6 (5.5%) |
1 (2.6%) |
5 (6.9%) |
|
Pathological Stage pN |
|
|
|
|
pN0 |
88 (80.0%) |
32 (84.2%) |
56 (77.8%) |
|
pN1mi |
7 (6.4%) |
3 (7.9%) |
4 (5.6%) |
p=0.71 |
pN1a |
14 (12.7%) |
3 (7.9%) |
11 (15.3%) |
|
pN3 |
1 (0.9%) |
0 (0.0%) |
1 (1.4%) |
|
Grading |
|
|
|
|
G1 |
15 (13.7%) |
7(18.4%) |
8 (11.1%) |
|
G2 |
68 (61.8%) |
24 (63.2%) |
44 (61.1%) |
p = 0.67 |
G3 |
21 (19.1%) |
6 (15.8%) |
15 (20.8%) |
|
Gx |
6 (5.4%) |
1 (2.6%) |
5 (7%) |
|
Adjuvant therapy Calculated on 109 patients |
|
|
|
|
None |
2 (1.8%) |
0 (0.0%) |
2 (2.8%) |
|
Chemotherapy |
6 (5.5%) |
2 (5.4%) |
4 (5.6%) |
p = 0.92 |
Endocrine therapy |
85 (78%) |
29 (78.4%) |
56 (77.7%) |
|
Chemotherapy + Endocrine therapy |
12 (11%) |
4 (10.8%) |
8 (11.1%) |
|
Chemotherapy + Trastuzumab |
4 (3.7%) |
2 (5.4%) |
2 (2.8%) |
|